

Media Release

Synthes Receives FDA Clearance for *chronOS*TM Strip Flexible Ceramic Osteoconductive Bone Void Filler

Solothurn/Switzerland, November 20, 2007

Synthes today announced the recent FDA 510(k) clearance of *chronOS*TM Strip for use in the spine for posterolateral fusions. *chronOS* Strip is expected to broaden the already successful *chronOS* line of synthetic ceramic bone graft substitutes.

chronOS Strip is designed to fill bony voids or gaps that are not intrinsic to the stability of the bony structure; such voids can be the result of a surgical procedure or traumatic injury. This new biomaterial offers surgeons increased handling options and leverages two areas of expertise for Synthes: osteoconductive ceramics and resorbable biocompatible polymers. The unique combination of these two materials into one implant offers surgeons a 100% synthetic composite graft containing no human or animal derived materials. *chronOS* Strip can be rolled, folded, cut or sutured intraoperatively, and then conformed to each patient's anatomy.

The perfusion of *chronOS* Strip with bone marrow aspirate provides a favorable environment for bony ingrowth. To facilitate this, each strip is sterile packaged in a perfusion pack that allows easy perfusion and homogenous saturation with the patient's bone marrow and/or blood. The perfusion pack can be connected to any standard syringe, such as the one found in the Synthes Bone Marrow Aspiration System. *chronOS* Strip may also be used in conjunction with autograft.

chronOS Strip is replaced with new bone in 6 - 18 months during the bone remodeling process, and the uniform, three-dimensional pore structure of the imbedded *chronOS* granules provides an ideal matrix for the ingrowth of bone. The Synthes *chronOS* line of 100% synthetic bone void fillers provides surgeons with excellent options for their bone grafting needs.

Synthes: A leading medical device company

Synthes is a leading global medical device company. We develop, produce and market instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.

For further information please contact

Gilgian Eisner, Investor Relations, Synthes, Inc.
Phone +41 32 720 4745, Fax +41 32 720 4811, e-mail ir.info@synthes.com

<http://www.synthes.com/>

Restrictions subject to US-Securities Law

SYNTHES MANAGEMENT BELIEVES CERTAIN STATEMENTS IN THIS PRESS RELEASE MAY CONSTITUTE “FORWARD-LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. THESE STATEMENTS INCLUDE BUT ARE NOT LIMITED TO THOSE WITH RESPECT TO THE POTENTIAL FOR SYNTHES TO OFFER NEW PRODUCTS AND MARKET EXISTING ONES, AS WELL AS THE EXPECTED SALES AND SALES GROWTH OF SYNTHES. THESE STATEMENTS ARE MADE ON THE BASIS OF MANAGEMENT’S VIEWS AND ASSUMPTIONS REGARDING FUTURE EVENTS AND BUSINESS PERFORMANCE AS OF THE TIME THE STATEMENTS ARE MADE. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED. SUCH DIFFERENCES MAY RESULT FROM THE ABILITY OF SYNTHES TO SUCCESSFULLY DEVELOP AND INTRODUCE NEW PRODUCTS AND SERVICES AND MARKET EXISTING PRODUCTS AND SERVICES IN A COMPETITIVE MARKETPLACE AND CHANGES IN THE ECONOMIC CONDITIONS THAT MAY AFFECT THE PERFORMANCE OF THE OPERATIONS OF SYNTHES. IN ADDITION, CHANGES IN COMPETITIVE CONDITIONS AND REGULATORY DEVELOPMENTS MAY AFFECT FUTURE BUSINESS PERFORMANCE, AND CHANGING MARKET CONDITIONS MAY AFFECT THE VALUATION OF SYNTHES SECURITIES. IN ADDITION, IT SHOULD BE NOTED THAT PAST FINANCIAL AND OPERATIONAL PERFORMANCE OF THE COMPANY IS NOT NECESSARILY INDICATIVE OF FUTURE FINANCIAL AND OPERATIONAL PERFORMANCE. SYNTHES UNDERTAKES NO OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.

THE SECURITIES OF SYNTHES, INC. HAVE BEEN OFFERED AND SOLD OUTSIDE THE UNITED STATES AND HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (“THE SECURITIES ACT”). SUCH SECURITIES MAY NOT BE OFFERED, SOLD OR TRANSFERRED IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED IN REGULATION S OF THE SECURITIES ACT), EXCEPT PURSUANT TO A REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT OR UNDER AN APPLICABLE EXEMPTION UNDER THE SECURITIES ACT. HEDGING TRANSACTIONS INVOLVING SUCH SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT. THE SYNTHES SECURITIES ARE DEEMED “RESTRICTED SECURITIES” AS THAT TERM IS DEFINED IN RULE 144 UNDER THE SECURITIES ACT.